Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Price to Sales: Premium ValuationElevated
Percentile Rank92
3Y CAGR+1062.4%
5Y CAGR+169.6%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
+1062.4%/yr
vs -19.1%/yr prior
5Y CAGR
+169.6%/yr
Recent acceleration
Acceleration
+1081.5pp
Accelerating
Percentile
P92
Near historical high
vs 5Y Ago
142.5x
Strong expansion
Streak
2 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 4125.96 | +2912.8% |
| 2024 | 136.95 | +10325.7% |
| 2023 | 1.31 | -50.0% |
| 2022 | 2.63 | -92.0% |
| 2021 | 32.83 | +13.4% |
| 2020 | 28.95 | -36.6% |
| 2019 | 45.65 | +644.8% |
| 2018 | 6.13 | +189.3% |
| 2017 | 2.12 | -68.6% |
| 2016 | 6.74 | - |